Beximco Pharmaceuticals Ltd.

beximcopharma.com

Beximco Pharmaceuticals Ltd (Beximco Pharma) is an emerging generic drug player committed to providing access to affordable medicines. Company’s state-of-the-art manufacturing facilities have been accredited by the regulatory authorities of Australia, European Union, Canada, and Brazil, among others, and it currently focuses on building presence in many emerging and developed markets around the world. Beximco Pharma is consistently building upon its portfolio and currently producing more than 500 products encompassing broad therapeutic categories and the Company has created strong differentiation by offering a range of high-tech, specialized products which are difficult to imitate.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharmacy Market

JACOBIO PHARMA TO COLLABORATE WITH MERCK ON CLINICAL TRIAL OF JAB-21822 IN COMBINATION WITH CETUXIMAB

Jacobio Pharma | October 13, 2022

news image

Jaco Jacobio announced it has entered into a clinical trial collaboration agreement with Merck on clinical study of combination therapy between Jacobio's KRAS G12C inhibitor JAB-21822 and Merck's epidermal growth factor receptor inhibitor Erbitux®. This clinical study aims to evaluate the efficacy of JAB-21822 in combination with cetuximab in patients with KRAS G12C-mutated colorectal cancer. Jacobio is the sponsor of the combination study, and Merck will provide cetux...

Read More

DECK 7 OPTIMIZES ITS STRATEGIC MARKETING FOR 2020 USING A REVISED ABM STRATEGY

DECK 7 | February 04, 2020

news image

Being one of the best lead-gen service providers in San Diego, California, DECK 7 is more data-focused than ever. The brand has optimized its strategic marketing approach by scaling ABM in a number of effective ways. By combining its time-tested ABM framework with a strong data-driven approach, DECK 7 is empowering numerous brands in maximizing growth and driving actionable results. DECK 7’s ABM prowess is defined by its skilled team members and their advanced approach to B2B marketing. Th...

Read More

Business Insights

BIOCYTOGEN EXPANDS PARTNERSHIP WITH MERCK KGAA, DARMSTADT, GERMANY

Biocytogen and Merck KGaA, Darmstadt, Germany | August 26, 2022

news image

Biocytogen Pharmaceuticals Co., Ltd. entered into a global licensing agreement with Merck KGaA, Darmstadt, Germany, for the use of Biocytogen’s RenMiceTM platform. Under the terms of the agreement, Merck KGaA, Darmstadt, Germany will have full access to Biocytogen’s RenMiceTM platform to discover and develop fully human antibody therapeutics for an unlimited number of drug targets. Merck KGaA, Darmstadt, Germany will be responsible for all clinical development, manufacturing, and com...

Read More

TACKLING THE INNOVATION CRISIS IN DRUG DISCOVERY AND DEVELOPMENT

Technology Networks | February 17, 2020

news image

Arctoris Ltd has announced a formal partnership with Molecule in order to tackle the ongoing innovation crisis faced by drug discovery and development across both industry and academia. Through its fully automated drug discovery platform, Arctoris aims to enable researchers and biotechnological entrepreneurs to design and remotely execute advanced cell-based, molecular biology and biochemical assays. Together with Molecule’s distributed IP ownership platform, which enables stakeholders in ...

Read More
news image

Pharmacy Market

JACOBIO PHARMA TO COLLABORATE WITH MERCK ON CLINICAL TRIAL OF JAB-21822 IN COMBINATION WITH CETUXIMAB

Jacobio Pharma | October 13, 2022

Jaco Jacobio announced it has entered into a clinical trial collaboration agreement with Merck on clinical study of combination therapy between Jacobio's KRAS G12C inhibitor JAB-21822 and Merck's epidermal growth factor receptor inhibitor Erbitux®. This clinical study aims to evaluate the efficacy of JAB-21822 in combination with cetuximab in patients with KRAS G12C-mutated colorectal cancer. Jacobio is the sponsor of the combination study, and Merck will provide cetux...

Read More
news image

DECK 7 OPTIMIZES ITS STRATEGIC MARKETING FOR 2020 USING A REVISED ABM STRATEGY

DECK 7 | February 04, 2020

Being one of the best lead-gen service providers in San Diego, California, DECK 7 is more data-focused than ever. The brand has optimized its strategic marketing approach by scaling ABM in a number of effective ways. By combining its time-tested ABM framework with a strong data-driven approach, DECK 7 is empowering numerous brands in maximizing growth and driving actionable results. DECK 7’s ABM prowess is defined by its skilled team members and their advanced approach to B2B marketing. Th...

Read More
news image

Business Insights

BIOCYTOGEN EXPANDS PARTNERSHIP WITH MERCK KGAA, DARMSTADT, GERMANY

Biocytogen and Merck KGaA, Darmstadt, Germany | August 26, 2022

Biocytogen Pharmaceuticals Co., Ltd. entered into a global licensing agreement with Merck KGaA, Darmstadt, Germany, for the use of Biocytogen’s RenMiceTM platform. Under the terms of the agreement, Merck KGaA, Darmstadt, Germany will have full access to Biocytogen’s RenMiceTM platform to discover and develop fully human antibody therapeutics for an unlimited number of drug targets. Merck KGaA, Darmstadt, Germany will be responsible for all clinical development, manufacturing, and com...

Read More
news image

TACKLING THE INNOVATION CRISIS IN DRUG DISCOVERY AND DEVELOPMENT

Technology Networks | February 17, 2020

Arctoris Ltd has announced a formal partnership with Molecule in order to tackle the ongoing innovation crisis faced by drug discovery and development across both industry and academia. Through its fully automated drug discovery platform, Arctoris aims to enable researchers and biotechnological entrepreneurs to design and remotely execute advanced cell-based, molecular biology and biochemical assays. Together with Molecule’s distributed IP ownership platform, which enables stakeholders in ...

Read More